Meditope Biosciences, Inc. Overview
Pro stress-test →Meditope Biosciences is a Pasadena-based biotechnology company with a proprietary antibody platform technology called "SnAP" (Site-specific, novel, Antibody Platform) that can turn antibodies into a LEGO-like system, allowing for attachment of toxins, proteins, radiolabels, and other molecules to antibodies with precision and control. The company is using this technology to develop a preclinical pipeline of cancer drugs including immuno-oncology products for prostate and bladder cancers.
Strategic Profile
Pro stress-test →Founded in 2011 and currently a Series A company, Meditope focuses on developing next-generation oncology therapeutics through its innovative platform. The company has raised a total of $5.22M across 2 funding rounds, with its first Series A round completed in February 2013. With a lean team focused on bioconjugation technology and antibody-drug conjugate development, Meditope positions itself in the competitive antibody therapeutics space.
Competitive Landscape
Pro stress-test →Competitors include Jazz Pharmaceuticals, Sana Biotechnology, and Kite Pharma in the broader oncology and antibody therapeutic space. More directly, Meditope competes with other antibody-drug conjugate (ADC) platforms and companies developing site-specific bioconjugation technologies such as Bicycle Therapeutics and ADC Therapeutics. The company's SnAP platform differentiates through non-chemical conjugation capabilities, but it remains early-stage compared to these more mature competitors.
Industry Context
Meditope Biosciences, Inc. operates in Antibody-drug conjugate (ADC) therapeutics.
Key facts
Founded: 2011 · Headquarters: Pasadena, US · Employees: 5 · Revenue: $4M (2026) · Market cap: N/A